Freedom from severe VOCs may be possible with CASGEVY ; 93.5% icon. of people (29 out of 31 people) did not have a severe VOC for at least 12 months in a row ...

Participant details: 52 people in the study received CASGEVY; Efficacy, or how well CASGEVY worked, was measured for 35 people at the time data were reviewed ...

Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older.

14 июн. 2024 г. · Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress.

The safety data are for the full analysis set, defined as the 44 patients who received CASGEVY. The efficacy data are for the primary efficacy set (n=31). This ...

14 июн. 2024 г. · Vertex presented long-term data showing the durability and effectiveness of Casgevy for patients who have taken the gene therapy for sickle cell disease.

† Interim analysis conducted based on April 2023 data cut with 43 patients having been administered Casgevy and 4 patients awaiting Casgevy infusion.

In the clinical trials, all treated patients achieved neutrophil engraftment and no patients received rescue CD34 + cells.

8 дек. 2023 г. · The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

There are no data on the effects of exagamglogene autotemcel on human fertility. Effects on male and female fertility have not been evaluated in animal studies.